Adult Acute Lymphoblastic Leukemia (ALL) – Treatment Recommendations (Excluding R‑ICE)

1. Regimen Appropriateness

R‑ICE (rituximab + ifosfamide + carboplatin + etoposide) is validated only for relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) and is not a standard regimen for adult ALL. 72 % overall response rates have been reported in DLBCL, where R‑ICE serves as a bridge to autologous stem‑cell transplantation. 1
Adult ALL requires disease‑specific intensive chemotherapy protocols (e.g., hyper‑CVAD or DFCI), which differ fundamentally in drug selection, dosing, and scheduling from lymphoma salvage regimens. [3][4]

Rituximab is indicated only in CD20‑positive B‑cell precursor ALL; CD20 expression is present in approximately 30‑50 % of such cases. [4][5]
When used in ALL, rituximab must be combined with an ALL‑specific chemotherapy backbone (e.g., hyper‑CVAD); it should not be paired with the ICE salvage regimen. [3][4]
The standard rituximab schedule for ALL is 375 mg/m² administered one day before chemotherapy, delivered as eight infusions over four cycles and integrated into the ALL treatment protocol. 3

First‑line treatment should consist of intensive ALL‑specific regimens (hyper‑CVAD or DFCI). Rituximab is added only when CD20 expression on blasts is ≥20 %. [3][5]
All systemic chemotherapy must be accompanied by intrathecal chemotherapy to prevent central‑nervous‑system relapse in every patient category. [3][4]

Conventional salvage chemotherapy for R/R ALL yields complete remission (CR) in only 20‑40 % of patients, with prolonged disease‑free survival in roughly 10‑15 %. 6
Immunotherapy is the preferred approach for relapsed disease, including blinatumomab (bispecific T‑cell engager), inotuzumab ozogamicin (anti‑CD22 antibody‑drug conjugate), and chimeric antigen receptor (CAR) T‑cell therapy. [5][6]
Nelarabine is specifically approved for relapsed/refractory T‑cell ALL and achieves CR rates of about 36 % in heavily pretreated patients. 6

Extrapolating lymphoma regimens (such as R‑ICE) to ALL is inappropriate because the underlying biology, treatment response patterns, and optimal drug combinations differ markedly. [1][6]
R‑ICE must not be used as first‑line therapy for any ALL subtype; even in CD20‑positive disease, rituximab must be combined with an ALL‑specific chemotherapy backbone. [3][4]
Assuming that all B‑cell malignancies respond similarly to rituximab‑based regimens is erroneous; the chemotherapy backbone is a critical determinant of efficacy. [3][4]

In CD20‑positive B‑cell precursor ALL with ≥20 % CD20 expression, adding rituximab to intensive ALL chemotherapy (e.g., hyper‑CVAD) improves 3‑year event‑free survival and is considered standard of care. [3][5]
For Burkitt leukemia/lymphoma, incorporation of rituximab into intensive chemotherapy (not R‑ICE) raises 3‑year event‑free survival from 62 % to 75 % and 3‑year overall survival from 70 % to 83 %. [3][4]